LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website: https://business.uoregon.edu/centers/lce

Clinical Trials

A Comparison of Accuvein to Standard IV Access in Children 0 to 24 Months of Age in the Pediatric ED

Not Applicable

Terminated

Conditions: Pediatric Disorder

Interventions: Device: Accuvein AV400

First Posted Date: 2015-03-06

Last Posted Date: 2018-04-23

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 23

Registration Number: NCT02381392

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

Phase 4

Completed

Conditions: Atherosclerosis

Interventions: Drug: Warfarin
Drug: rivaroxaban

First Posted Date: 2015-03-03

Last Posted Date: 2024-10-14

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 110

Registration Number: NCT02376010

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

Hormonal Mechanisms of Sleep Restriction

Early Phase 1

Completed

Conditions: Insulin Resistance

Interventions: Drug: Ketoconazole
Drug: Hydrocortisone
Drug: Testosterone
Drug: Placebo for ketoconazole
Drug: Placebo for hydrocortisone
Drug: Placebo for testosterone

First Posted Date: 2014-10-06

Last Posted Date: 2023-11-07

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 40

Registration Number: NCT02256865

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

Dietary Protein Requirements in Hemodialysis Patients

Not Applicable

Completed

Conditions: End-Stage Renal Disease
Chronic Renal Failure

Interventions: Other: Protein Diet

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-18

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 13

Registration Number: NCT02194114

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: apixaban
Drug: warfarin

First Posted Date: 2014-03-18

Last Posted Date: 2019-04-23

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 66

Registration Number: NCT02090075

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: BPS-314d-MR

First Posted Date: 2013-10-21

Last Posted Date: 2020-10-20

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 1

Registration Number: NCT01966302

Locations: 🇺🇸
Los Angeles Biomedical research Institute, Torrance, California, United States

Reproductive Aging and Obstructive Sleep Apnea

Not Applicable

Withdrawn

Conditions: Obstructive Sleep Apnea

Interventions: Device: Active CPAP
Device: Sham CPAP

First Posted Date: 2013-05-10

Last Posted Date: 2016-01-12

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Registration Number: NCT01850992

Locations: 🇺🇸
LA Biomedical Research Institute, Torrance, California, United States

Minocycline and Proteinuria in Diabetic Nephropathy

Not Applicable

Conditions: Diabetic Nephropathy

Interventions: Drug: placebo
Drug: Minocycline 100 mg po bid for 6 months

First Posted Date: 2013-01-30

Last Posted Date: 2015-05-21

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 30

Registration Number: NCT01779089

Locations: 🇺🇸
Los Angeles Biomedical Reaearch Institute at Harbor-UCLA Medical Center, Torrance, California, United States

Intranasal Fentanyl as an Analgesic for Cystoscopic Procedures

Phase 4

Completed

Conditions: Pain

Interventions: Drug: Fentanyl
Drug: saline

First Posted Date: 2012-10-16

Last Posted Date: 2015-08-20

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 71

Registration Number: NCT01708122

Locations: 🇺🇸
Harbor UCLA Medical Center Urology Clinic, Torrance, California, United States

Fosrenol and Phosphorus Balance - Lanthanum Carbonate

Not Applicable

Completed

Conditions: Chronic Kidney Failure
End-stage Renal Disease
Disorders Associated With Peritoneal Dialysis

Interventions: Drug: lanthanum carbonate

First Posted Date: 2012-04-20

Last Posted Date: 2017-05-09

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 9

Registration Number: NCT01581996

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy